Autopsy report · NCT00662597
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Cause of deathNo reason given
Life of this trial
- Ran for about 2 years 1 month before it stopped.
- 1,285 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- ASA404; Placebo; carboplatin; Paclitaxel
- Participants
- 1,285
- Sites
- 248
- Countries
- Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Hungary and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.